A Study to Investigate the Pharmacokinetics, Pharmacodynamic Effects, Safety and Tolerability of Repeated Dosing of RO5459072 in Volunteers With Celiac Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

March 6, 2016

Primary Completion Date

August 28, 2016

Study Completion Date

August 28, 2016

Conditions
Celiac Disease
Interventions
DRUG

Placebo

With the exception of the mornings of Days 7 and 21, placebo capsules will be taken orally with a glass of still water in the morning and evening under fed conditions. On the mornings of Days 7 and 21, placebo will be administered under fasted conditions (overnight fast of at least 8 hours before dosing).

DRUG

RO5459072

With the exception of the mornings of Days 7 and 21, RO5459072 capsules will be taken orally with a glass of still water in the morning and evening under fed conditions. On the mornings of Days 7 and 21, RO5459072 will be administered under fasted conditions (overnight fast of at least 8 hours before dosing).

Trial Locations (1)

NW10 7EW

Hammersmith Medicines Research Ltd., London

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT02679014 - A Study to Investigate the Pharmacokinetics, Pharmacodynamic Effects, Safety and Tolerability of Repeated Dosing of RO5459072 in Volunteers With Celiac Disease | Biotech Hunter | Biotech Hunter